225 results on '"Oelschlägel, Uta"'
Search Results
2. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
3. An Explainable AI System for the Diagnosis of High Dimensional Biomedical Data
4. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
5. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
6. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
7. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation
8. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
9. Morphology and Flow Cytometry
10. An Explainable AI System for the Diagnosis of High-Dimensional Biomedical Data.
11. P528: CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?
12. Mutated IKZF1is an independent marker of adverse risk in acute myeloid leukemia
13. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease
14. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
15. Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation
16. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
17. Gut Microbiome, Metabolome and Immune Changes in Myelodysplastic Syndromes
18. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
19. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method
20. Flow cytometry datasets consisting of peripheral blood and bone marrow samples for the evaluation of explainable artificial intelligence methods
21. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
22. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft- versus-host-disease
23. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
24. The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes.
25. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial
26. Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia
27. The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes
28. Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms
29. Prediction of hematopoietic stem cell yield after mobilization with granulocyte–colony-stimulating factor in healthy unrelated donors
30. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice
31. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
32. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells
33. Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up
34. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
35. PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells
36. Long-Term Mixed Chimerism After Ex Vivo / In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms.
37. SOME LIMITATIONS IN THE DETECTION OF RESIDUAL ANEUPLOID CELLS WITH DNA QUANTIFICATION ON IMMUNOPHENOTYPED CELLS BY FLOW CYTOMETRY
38. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System
39. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
40. JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter
41. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor
42. The Incidence of DNA Aneuploidy in Multiple Myeloma Does Not Correlate With Stage of Disease
43. Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes
44. T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing
45. Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
46. RELATIONS BETWEEN IL-3-INDUCED PROLIFERATION AND IN VITRO CYTOKINE SECRETION OF BONE MARROW CELLS FROM AML PATIENTS
47. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples
48. Machine Learning Approach Identifies Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS)
49. Assessment of the T cell receptor repertoire in long-term platelet donors by next generation sequencing
50. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.